Jill Feldman
@jillfeldman4.bsky.social
2.2K followers 760 following 15 posts
Lung Cancer Patient and Advocate, Co-Founder @EGFRResisters, #LCSM #LungCancer #EndStigma #EndJewHate
Posts Media Videos Starter Packs
jillfeldman4.bsky.social
Deadline is approaching!

Are you doing research in #EGFR+ #lungcancer — OR mentoring someone who is — submit an abstract to the EGFR Resisters Research Summit
Concepts welcome
Deadline-August 8.
Submit Abstract - ceconcepts.com/egfr-summit

#NSCLC #ThoracicOnc #HOFellows #EGFRResisters
#OncoAlert
Reposted by Jill Feldman
aspire-cop.bsky.social
Heading to #ASCO25 this year? Be sure to join us for the first ever #ASPIRE Community of Practice on Friday, May 30th: 4-6pm CST in E253cd. We have a great agenda and opportunity to connect with other #irAE aficionados @ascocancer.bsky.social @funchainmd.bsky.social www.asco.org/annual-meeti...
Reposted by Jill Feldman
pallonccop.bsky.social
Welcome #pallonc #supponc folks to the official Blue Sky account for ASCO supported #PallOncCoP. Please follow for official Zoom meeting events, in-person conference meet ups like pic #ASCO24 and sharing the latest science in comfort and cure.
Reposted by Jill Feldman
tingtingzhang.bsky.social
I will co-chair with Prof Maryam Lustberg on June 26th AM
"Workshop 1: Partnering with patients in managing chronic toxicities of cancer and its treatment."
bringing together multidisciplinary professionals, cancer patients, survivors and carers to compare best practices for management toxicities.
MASCC25
jillfeldman4.bsky.social
My Guiding Compass in Advocacy:

Speak up, but do it with respect.
Challenge, but do it with understanding.
And always push forward with purpose — Real change happens through conversation, not confrontation.

I was 28 when my mom died, but her profound wisdom always guides me 💙
Reposted by Jill Feldman
Reposted by Jill Feldman
tingtingzhang.bsky.social
ASCO has a palliative care community of practice in which a patient advocate pillar was organized with @jillfeldman4.bsky.social, Ameish, and I as members. I have served since September 2023 as the lead and will hand over the role later this year.
Reposted by Jill Feldman
tingtingzhang.bsky.social
Please email [email protected] to be added to the listserv.
jillfeldman4.bsky.social
Words Matter isn't just a catchphrase. It is a simple yet profound truth when talking about #lungcancer

Thank you, Drs Jamie Ostroff & Smita Banerjee, for your efforts to develop a training that offers strategies for empathic communication to ⬇️ stigma bit.ly/4gWH1Si

#LCSM #EndStigmaNow
Helping Health Professionals Reduce Lung Cancer Stigma
Researchers have developed a training program to help health providers reduce lung cancer stigma and have launched a clinical trial to test the training.
bit.ly
jillfeldman4.bsky.social
THIS!

Easy-to-use, available regimen significantly ⬇️ frequency & severity of Grade 2+ AEs SOC for patients on first-line Ami/Lazer.

Like “Stay ahead of the pain,” “Stay ahead of the side effects” boosts QOL & ⬇️ dose interrupt/discontine—a win for everyone. 👏
#LCSM #SuppOnc
bit.ly/4jiKwUz
COCOON study meets primary endpoint demonstrating statistically significant and clinically meaningful reduction in dermatologic reactions with easy-to-use prophylactic regimen for patients with EGFR-m...
bit.ly
jillfeldman4.bsky.social
What a pleasure it was to meet Donghoon Shin! His passion and desire to learn from patient advocates was genuine and impressive. The future of #lungcancer research is bright😎
#LCSM #EGFR
ivyrianomd.bsky.social
Congrats Donghoon Shin on receiving an honorable mention at the @EGFRSummit Your research and passion for the field are truly impressive #ProudMentor

Huge shoutout to @EGFRResisters for giving trainees a platform to showcase their work! #LCSM 🙌🏼 @jillfeldman4.bsky.social
Reposted by Jill Feldman
advocatecollab.bsky.social
ICYMI
"We must rethink how we define progress in oncology"
#Oncosky #Cansky #Pallonc
jillfeldman4.bsky.social
Innovation shouldn't come at the expense of patient-centered care!
Great article about prioritizing what matters to patients (QOL/OS/⬇️ burdens). It underscores palliative care being viewed as essential, not ancillary.
We must rethink how we define progress in #oncology
#pallonc #LCSM
bit.ly/3OJQuQB
The trade-off between accelerated cancer drug approvals and patient preferences
Cancer care stands at a critical juncture where the urgency of rapid drug approvals must be balanced against the need for enduring patient-centric benefits. Robin Forrest and colleagues1 conducted a d...
bit.ly
Reposted by Jill Feldman
ronilynnwrites.bsky.social

“The most common cause of death from cancer is from lung cancer…yet just 16% of eligible people get screened for lung cancer, far lower than screening rates for colorectal or breast cancer. “ #medsky ktul.com/news/nation-...
More people surviving lung cancer, but work remains in screening and biomarker testing
The American Lung Association has released its annual "State of Lung Cancer" report.
ktul.com
jillfeldman4.bsky.social
Innovation shouldn't come at the expense of patient-centered care!
Great article about prioritizing what matters to patients (QOL/OS/⬇️ burdens). It underscores palliative care being viewed as essential, not ancillary.
We must rethink how we define progress in #oncology
#pallonc #LCSM
bit.ly/3OJQuQB
The trade-off between accelerated cancer drug approvals and patient preferences
Cancer care stands at a critical juncture where the urgency of rapid drug approvals must be balanced against the need for enduring patient-centric benefits. Robin Forrest and colleagues1 conducted a d...
bit.ly
Reposted by Jill Feldman
jia-b.bsky.social
Only this week a patient asked me if thought she was foolish for declining further treatment. She is not foolish, it is the right decision for her.
jillfeldman4.bsky.social
It was an honor to co-author this article
bit.ly/40WN9Vr
It emphasizes the profound impact of a #lungcancer dx, highlighting the multifaceted challenges patients/families face.
It's time to transform the “one-way ticket” into an experience of hope, support & compassionate care.
#LCAM #LCSM
Lung cancer—a one-way ticket
The physician’s duty is not to stave off death or return patients to their old lives, but to take into our arms a patient and family whose lives have disin
bit.ly
jillfeldman4.bsky.social
It was an honor to co-author this article
bit.ly/40WN9Vr
It emphasizes the profound impact of a #lungcancer dx, highlighting the multifaceted challenges patients/families face.
It's time to transform the “one-way ticket” into an experience of hope, support & compassionate care.
#LCAM #LCSM
Lung cancer—a one-way ticket
The physician’s duty is not to stave off death or return patients to their old lives, but to take into our arms a patient and family whose lives have disin
bit.ly
jillfeldman4.bsky.social
Looking forward to it!
Reposted by Jill Feldman
realbowtiedoc.bsky.social
Today's the day! Our last PallOncCoP meeting of 2024! Don't miss it. Not too late to DM📨 for Zoom 🔗. Always stay in the know by sending your prof email to [email protected] to be added to our listserv.

@darcyburbage.bsky.social
@tingtingzhang.bsky.social
@jillfeldman4.bsky.social
sarahlowry.bsky.social
Looking forward to sharing our experience next week!
realbowtiedoc.bsky.social
Join our #PallOncCoP next Wednesday for an interdisciplinary conversation on mentorship feat @ericroeland.bsky.social and @sarahlowry.bsky.social. DM for details or email [email protected] to be added to the listserv.
hapc hpm #pallonc #supponc CanSky MedSky
jillfeldman4.bsky.social
The #lungcancer screening team at RushCancer Center
has had a 50% uptake in screening for the 3rd year! Congratulations to Annie and the team, and thank you for your tireless efforts to raise awareness about lung cancer screening!
#LCSM #LCAM #EarlyDetectionSavesLives
jillfeldman4.bsky.social
📢 The @ASCO released updated living guidelines for treating stage IV #NSCLC with driver alterations! ascopubs.org/doi/10.1200/....

This is no easy feat, but it was an honor to work alongside exceptional experts dedicated to providing the most up-to-date, evidence-based guidance.
#LCSM #LCAM